Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BHVN

Biohaven Ltd

Feb 06 • 04:00PM ET

11.60

+0.84 7.81 %

Healthcare • Biotechnology • USA • NYSE

Peers: VRTX AMGN REGN GILD BMRN NBIX ALNY INCY SRPT EXEL

| Held by: XBI IWM VXF PINK IBB IWO SCHA VTWO VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-7.60	Insider Own	13.01%	Shs Outstand	145.19M	Perf Week	-1.94%
Market Cap	1.68B	Forward P/E	-	EPS next Y	-3.11	Insider Trans	30.52%	Shs Float	126.30M	Perf Month	-1.19%
Enterprise Value	1.74B	PEG	-	EPS next Q	-1.19	Inst Own	61.62%	Short Float	16.41%	Perf Quarter	39.09%
Income	-780.11M	P/S	-	EPS this Y	28.78%	Inst Trans	-1.44%	Short Ratio	5.61	Perf Half Y	-23.83%
Sales	0.00M	P/B	-	EPS next Y	53.01%	ROA	-169.65%	Short Interest	20.73M	Perf YTD	2.75%
Book/sh	-0.16	P/C	6.46	EPS next 5Y	38.33%	ROE	-522.08%	52W High	44.28 -73.80%	Perf Year	-70.36%
Cash/sh	1.80	P/FCF	-	EPS past 3/5Y	-40.84% -49.78%	ROIC	-267.62%	52W Low	7.48 55.08%	Perf 3Y	-38.36%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.96% 9.08%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	18.76%	Oper. Margin	-	ATR (14)	0.96	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.86	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.04	Recom	1.65
Dividend Gr. 3/5Y	- -	Current Ratio	2.86	EPS Q/Q	3.50%	SMA20	-3.94%	Beta	3.54	Target Price	20.94
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	3.94%	Rel Volume	0.66	Prev Close	10.76
Employees	256	LT Debt/Eq	-	Earnings	Nov 10 BMO	SMA200	-18.12%	Avg Volume	3.70M	Price	11.60
IPO	May 04, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.73% -100.00%	Trades		Volume	2,441,731	Change	7.81%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-26	Initiated	Goldman	Buy	$23
Jan-21-26	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$22
Dec-03-25	Downgrade	H.C. Wainwright	Buy → Neutral	$11
Nov-26-25	Downgrade	UBS	Buy → Neutral	$11
Nov-06-25	Downgrade	Bernstein	Outperform → Mkt Perform	$9
Nov-05-25	Downgrade	BofA Securities	Buy → Neutral	$10
Sep-17-25	Initiated	Citigroup	Buy	$28
Sep-03-25	Initiated	Raymond James	Strong Buy	$75
May-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$21
Feb-11-25	Initiated	Deutsche Bank	Buy	$65
Sep-16-24	Initiated	Jefferies	Buy	$57
Sep-04-24	Initiated	Bernstein	Outperform	$55
Jul-24-24	Initiated	Morgan Stanley	Overweight	$58
Feb-16-24	Initiated	RBC Capital Mkts	Outperform	$62
Feb-06-24	Initiated	UBS	Buy	$59
Dec-22-23	Initiated	H.C. Wainwright	Buy	$50
Dec-08-23	Initiated	Robert W. Baird	Outperform	$58
Jan-24-23	Initiated	SVB Securities	Outperform	$24
Jan-04-23	Initiated	JP Morgan	Overweight	$23
Dec-02-22	Initiated	BTIG Research	Buy	$24

Show Previous Ratings

Feb-06-26 08:07AM	Here Are Fridays Top Wall Street Analyst Research Calls: Amazon.com, Caterpillar, Estee Lauder, JPMorgan, Norfolk Southern, Roku, Snap, Vistra, and More (24/7 Wall St.) +7.81%
Jan-22-26 09:40AM	Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? (Zacks) +6.92%
Jan-14-26 09:48PM	Biohaven (BHVN) Stock Is Trending Overnight - Here's What You Should Know (Benzinga) +6.65%
Jan-12-26 11:15AM	Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) +6.57%
Jan-07-26 07:00AM	Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 (PR Newswire) +22.04%
02:56PM	Loading…
Dec-26-25 02:56PM	Christmas Week Brings S&P 500 Records, Tech Volatility (Schaeffer's Research)
02:14PM	These Stocks Are Moving the Most Today: Nvidia, Apple, Tesla, Coupang, Micron, Lam Research, Newmont, Moderna, and More (Barrons.com)
10:25AM	Biohaven Stock Gaps Lower on Failed Phase 2 Drug Trial (Schaeffer's Research)
08:18AM	Biohaven sinks on disappointing trial and other early movers (MarketWatch)
07:39AM	These Stocks Are Moving the Most Today: Nvidia, Micron, Nike, Tesla, Biohaven, Coupang, and More (Barrons.com)
06:07AM	S&P Futures Muted in Thin Post-Christmas Trade (Barchart)
04:27AM	Stock Market Today: Dow, S&P 500 set to hover near fresh records in thin holiday trading; silver, gold and copper rally continue, industrial metals also climb (MarketWatch)
Dec-24-25 01:00PM	Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder (PR Newswire)
09:55AM	Wall Street Analysts Predict an 88.57% Upside in Biohaven Ltd. (BHVN): Here's What You Should Know (Zacks)
Dec-19-25 12:00PM	Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know (Zacks)
07:00AM	Loading…
Dec-11-25 07:00AM	Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress (PR Newswire) +7.92%
Dec-04-25 09:55AM	How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 127.52% (Zacks) +5.37%
Dec-03-25 09:15AM	Here Are Wednesdays Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendys and More (24/7 Wall St.)
Nov-26-25 09:43AM	Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls (The Fly)
Nov-24-25 08:40AM	Jim Cramer on Biohaven: "The Stock Seems Very Low to Me" (Insider Monkey)
Nov-20-25 12:37PM	Biohaven Insiders Bet $33 Million on a Turnaround (MarketBeat)
Nov-18-25 09:45AM	Carl Icahn Makes Another Huge Insider Purchase (24/7 Wall St.) +14.27%
Nov-16-25 10:13PM	William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth (Insider Monkey)
Nov-13-25 04:05PM	Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M (PR Newswire)
Nov-12-25 07:15AM	Biohaven Announces Pricing of $175 Million Public Offering of Common Shares (PR Newswire) -6.69%
Nov-11-25 04:05PM	Biohaven Announces Proposed Public Offering of Common Shares (PR Newswire) +9.37%
Nov-10-25 06:58AM	Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments (PR Newswire) -5.69%
Nov-05-25 04:28PM	Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Drug (Investor's Business Daily) -40.22%
06:59AM	Knocked back by the FDA, Biohaven turns to major cost cuts (BioPharma Dive)
Nov-04-25 08:06PM	FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia (PR Newswire) -6.06%
09:33AM	Loading…
Sep-17-25 09:33AM	Netflix upgraded, Five Below initiated: Wall Street's top analyst calls (The Fly) +8.97%
Sep-14-25 05:30AM	Biotech stocks: Who wins and who loses if RFK, Jr. goes (Investing.com)
Sep-09-25 04:14PM	Shareholders of Biohaven Ltd. (BHVN): Protect Your Rights Before September 12, 2025 - Contact Levi & Korsinsky (Newsfile)
Sep-03-25 05:48PM	Biohaven Ltd. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BHVN (Business Wire)
12:01PM	Biohavens rare disease drug is ready to ship on Day 1 following FDA approval (BioPharma Dive)
Aug-22-25 06:18PM	Why Biohaven Stock Zoomed More Than 6% Higher Today (Motley Fool) +6.34%
04:15PM	Biohaven Surges After FDA Cancels Key Meeting. But Is It Good News? (Investor's Business Daily)
09:14AM	Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting (Benzinga)
06:27AM	FDA cancels adcomm on Biohaven drug; Catalent lays off staff (BioPharma Dive)
Aug-20-25 10:40AM	RBC says PTC Therapeutics CRL may signal difficulty for Biohaven (TipRanks)
Aug-18-25 04:55PM	Investors Urged to Contact Levi & Korsinsky for Information Before September 12, 2025 - Biohaven Ltd. (BHVN) (Newsfile)
Aug-17-25 11:41PM	Leerink Lowers Biohaven (BHVN) PT to $50 Following Q2 Report, Acknowledging Positive Pipeline Progress (Insider Monkey)
Aug-11-25 07:00AM	Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments (PR Newswire) -9.02%
Aug-08-25 04:23PM	Biohaven Ltd. (BHVN) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before September 12, 2025 (Newsfile)
Jul-29-25 08:45AM	Shareholders of Biohaven Ltd. Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN (PR Newswire)
Jul-21-25 04:37PM	Did You Lose Money on Biohaven Ltd. (BHVN)? Levi & Korsinsky Urges Investors to Act Before September 12, 2025 (Newsfile)
Jul-15-25 08:59AM	Biohaven, Bexorg Partner to Accelerate CNS Drug Discovery Using Novel Whole-Brain Platform (Insider Monkey) -6.55%
Jun-10-25 02:00PM	Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development (GlobeNewswire)
May-29-25 07:01AM	Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor (PR Newswire)
12:16AM	Biohaven Ltd. (BHVN)'s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy (Insider Monkey)
May-28-25 03:00PM	Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN) (PR Newswire)
07:30AM	Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors (PR Newswire)
May-15-25 06:03PM	Why Biohaven Stock Dove by Nearly 20% on Thursday (Motley Fool) -19.53%
02:06PM	Biohaven Plunges On A Surprise FDA Twist For Its Rare-Disease Drug (Investor's Business Daily)
01:22PM	Why Is Biohaven Stock Falling On Thursday? (Benzinga)
May-14-25 06:43PM	FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia (PR Newswire)
May-12-25 04:05PM	Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments (PR Newswire) -5.11%
May-09-25 08:49AM	Biohaven Ltd. (BHVN): Among Stocks That Will Bounce Back According To Analysts (Insider Monkey)
May-05-25 08:00AM	Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict (Seeking Alpha)
Apr-28-25 01:16PM	Why BioHaven Stock Is Soaring Today (Motley Fool) +9.58%
07:30AM	Biohaven Announces Investment up to $600 Million by Oberland Capital (PR Newswire)
Apr-26-25 12:10PM	Biohaven share price undervaluing pipeline potential, says RBC Capital (TipRanks)
Apr-25-25 05:10PM	Why Biohaven Stock Plummeted by More Than 15% Today (Motley Fool) -15.21% +9.58%
Apr-23-25 06:12PM	Jim Cramer Says Biohaven (BHVN) Is "Too Cheap" and He's a Buyer at $21 (Insider Monkey) +9.24%
01:02PM	Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-18-25 03:36AM	Xenon- A Later Stage Story (Seeking Alpha)
Apr-17-25 11:07AM	Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade (Seeking Alpha) +9.05%
Apr-05-25 09:00AM	Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting (PR Newswire)
Apr-03-25 09:30AM	Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March (Motley Fool) -13.22%
Apr-01-25 11:55AM	American Century Companies boosts stake in Biohaven, ETF Daily News says (TipRanks) -5.99%
Mar-26-25 07:00AM	Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire)
Mar-09-25 04:37PM	Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025 (Insider Monkey)
Mar-07-25 10:31AM	Biohaven price target lowered to $63 from $69 at Morgan Stanley (TipRanks)
Mar-04-25 04:50PM	Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity (Investor's Business Daily)
Mar-03-25 07:31AM	Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 (PR Newswire) -13.77%
07:30AM	Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-11-25 06:42PM	Why Biohaven Stock Triumphed on Tuesday (Motley Fool) +11.19%
04:11PM	Biohaven Just Hurdled An FDA Setback And Its Moving Lines (Investor's Business Daily)
01:29PM	Why Biohaven (BHVN) Stock Is Rallying Today (Insider Monkey)
07:30AM	Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia (PR Newswire)
Jan-24-25 05:48PM	Pfizer to Pay $60 Million in Kickback, False Claims Settlement (The Wall Street Journal)
Jan-13-25 11:15AM	Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy (PR Newswire)
Jan-12-25 08:04PM	Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs (GlobeNewswire)
Jan-07-25 05:54PM	Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-17-24 02:23PM	Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval (Benzinga) -5.60%
06:06AM	Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-16-24 07:30AM	Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates (PR Newswire) +7.72%
Dec-06-24 07:30AM	Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting (PR Newswire)
Nov-25-24 11:51AM	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga)
07:30AM	Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity (PR Newswire)
Nov-12-24 04:05PM	Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments (PR Newswire)
Oct-07-24 04:13PM	Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily) +10.75%
09:41AM	Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily)
Oct-02-24 04:05PM	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
Oct-01-24 06:00AM	Biohaven Announces Pricing of $250 Million Public Offering of Common Shares (PR Newswire)
Sep-30-24 04:05PM	Biohaven Announces Proposed Public Offering of Common Shares (PR Newswire)
07:30AM	Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine (PR Newswire)
Sep-23-24 07:30AM	Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) (PR Newswire) +13.74%
Sep-20-24 07:09PM	Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia (PR Newswire)
Aug-08-24 08:21PM	Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In? (Insider Monkey) +5.93% +6.25%

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gentile Kimberly	SVP, Clinical Operations	Jan 05 '26	Option Exercise	0.00	3,750	0	101,513	Jan 07 09:34 PM
Buten Matthew	Chief Financial Officer	Jan 05 '26	Option Exercise	0.00	4,250	0	198,246	Jan 07 09:33 PM
Coric Vlad	Chief Executive Officer	Jan 05 '26	Option Exercise	0.00	14,250	0	1,811,398	Jan 07 09:32 PM
Car Bruce	Chief Scientific Officer	Jan 05 '26	Option Exercise	0.00	4,750	0	10,096	Jan 07 09:32 PM
Clark George C.	VP, Chief Accounting Officer	Jan 05 '26	Option Exercise	0.00	2,500	0	68,095	Jan 07 09:31 PM
Clark George C.	VP, Chief Accounting Officer	Nov 17 '25	Buy	8.52	17,000	144,770	20,000	Nov 18 07:29 AM
Bailey Gregory	Director	Nov 13 '25	Buy	7.50	400,000	3,000,000	2,020,071	Nov 17 07:31 AM
CHILDS JOHN W	Director	Nov 13 '25	Buy	7.50	3,333,333	24,999,998	5,653,904	Nov 17 07:30 AM
Coric Vlad	Chief Executive Officer	Nov 13 '25	Buy	7.50	666,666	4,999,995	1,195,275	Nov 17 07:30 AM
CHILDS JOHN W	Director	Mar 04 '25	Buy	30.47	32,700	996,238	2,320,571	Mar 05 07:01 AM

Open in Screener

SER

Serina Therapeutics Inc

Feb 06 • 04:00PM ET

2.37

-0.10 -4.05 %

Healthcare • Biotechnology • USA • AMEX

SER Serina Therapeutics Inc daily Stock Chart

Peers: MRK LLY BMY JNJ AMGN PFE GILD REGN VRTX BIIB

Index	-	P/E	-	EPS (ttm)	-	Insider Own	49.43%	Shs Outstand	10.54M	Perf Week	-27.08%
Market Cap	25.56M	Forward P/E	-	EPS next Y	-1.82	Insider Trans	-3.05%	Shs Float	5.39M	Perf Month	-2.07%
Enterprise Value	24.91M	PEG	-	EPS next Q	-0.50	Inst Own	4.30%	Short Float	1.58%	Perf Quarter	-45.27%
Income	-	P/S	-	EPS this Y	-37.75%	Inst Trans	-6.03%	Short Ratio	0.07	Perf Half Y	-56.51%
Sales	-	P/B	-	EPS next Y	12.50%	ROA	-	Short Interest	0.09M	Perf YTD	23.89%
Book/sh	-0.30	P/C	2.97	EPS next 5Y	2.49%	ROE	-	52W High	7.92 -70.08%	Perf Year	-48.70%
Cash/sh	0.80	P/FCF	-	EPS past 3/5Y	42.71% 33.30%	ROIC	-	52W Low	1.71 38.59%	Perf 3Y	-90.37%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	11.87% -49.63%	Gross Margin	-	Volatility	17.52% 13.55%	Perf 5Y	-96.34%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	55.34%	Oper. Margin	-	ATR (14)	0.40	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.31	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.74	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.31	EPS Q/Q	-186.55%	SMA20	-14.76%	Beta	1.23	Target Price	11.00
Payout	-	Debt/Eq	1.82	Sales Q/Q	-100.00%	SMA50	-17.55%	Rel Volume	0.26	Prev Close	2.47
Employees	13	LT Debt/Eq	0.09	Earnings	Nov 13 BMO	SMA200	-49.59%	Avg Volume	1.30M	Price	2.37
IPO	Nov 29, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	15.09% -	Trades		Volume	342,212	Change	-4.05%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-14-25	Initiated	H.C. Wainwright	Buy	$15

Feb-03-26 06:00AM	Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event (GlobeNewswire)
Jan-29-26 12:09AM	What Sparked Serina Therapeutics (SER) 35% After-Hours Surge? (Benzinga) +30.15%
Jan-28-26 04:12PM	Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease (GlobeNewswire)
Jan-15-26 04:30PM	Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity (GlobeNewswire) +15.24%
Dec-11-25 04:15PM	Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry (GlobeNewswire)
04:30PM	Loading…
Dec-10-25 04:30PM	Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program (GlobeNewswire)
Nov-13-25 06:10AM	Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-03-25 06:05AM	Serina Therapeutics Provides Regulatory Update on SER-252 Program (GlobeNewswire) -6.40%
Oct-08-25 11:00AM	Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors (GlobeNewswire)
Oct-06-25 04:15PM	Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease (GlobeNewswire)
Sep-09-25 03:20PM	Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease (GlobeNewswire)
Sep-08-25 06:00AM	Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-26-25 04:52AM	These Stocks Are Moving the Most Today: Interactive Brokers, Talen Energy, Palantir, Nvidia, Serina Therapeutics, and More (Barrons.com)
Aug-25-25 04:15PM	Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway (GlobeNewswire)
Aug-11-25 04:30PM	Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) -7.44% +7.06%
06:44AM	Loading…
Jul-29-25 06:44AM	Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD) (GlobeNewswire)
Jul-28-25 06:00AM	Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire) +5.83%
Jul-10-25 04:10PM	Serina Therapeutics Makes Grant to New Employee Under Inducement Plan (GlobeNewswire)
Jul-01-25 04:15PM	Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting (GlobeNewswire)
Jun-23-25 07:24PM	Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025 (GlobeNewswire) +5.95%
Jun-17-25 08:30PM	UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42 (GlobeNewswire)
06:00AM	Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42 (GlobeNewswire)
Jun-09-25 04:05PM	Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" (GlobeNewswire)
May-22-25 04:50PM	Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors (GlobeNewswire) +8.87%
May-14-25 03:15PM	Serina Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire)
May-08-25 04:23PM	Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-29-25 06:00AM	Serina Therapeutics to Present at JonesResearch Virtual CNS Day (GlobeNewswire)
Apr-15-25 06:30AM	Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit (GlobeNewswire)
Apr-08-25 04:30PM	Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease (GlobeNewswire)
Apr-07-25 06:30AM	Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire)
04:30PM	Loading…
Mar-24-25 04:30PM	Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
06:30AM	Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting (GlobeNewswire)
Feb-12-25 04:15PM	Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors (GlobeNewswire)
Feb-03-25 04:30PM	Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients (GlobeNewswire) -5.91%
Jan-15-25 04:05PM	Serina Therapeutics Announces Sale of UniverXome Subsidiary (GlobeNewswire)
Jan-14-25 05:25PM	Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors (GlobeNewswire)
Dec-16-24 06:00AM	Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024 (GlobeNewswire) -7.98%
Dec-11-24 06:05AM	Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity and Toxicity Summit (GlobeNewswire) -9.16%
06:05AM	Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit (GlobeNewswire)
Dec-02-24 05:22PM	Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients (GlobeNewswire) -9.52% +19.16%
Nov-12-24 05:00PM	Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-11-24 05:40PM	Serina Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +20.87%
Oct-02-24 08:30AM	Serina Therapeutics to Present at the 14th Annual Injectables Summit (GlobeNewswire)
Sep-04-24 06:42PM	Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-20-24 07:01PM	Director Gregory Bailey Acquires 19,200 Shares of Serina Therapeutics Inc (SER) (GuruFocus.com)
Aug-09-24 04:15PM	Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -5.17% -10.13%
Jul-29-24 08:30AM	Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit (GlobeNewswire)
Jul-18-24 05:00PM	Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation (GlobeNewswire) -18.15% +9.84%
May-15-24 07:30AM	Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse® for Advanced Parkinsons Disease (GlobeNewswire)
May-14-24 04:05PM	Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +11.13%
Apr-17-24 04:05PM	Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman (GlobeNewswire) -9.64%
Mar-26-24 05:04PM	Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics (GlobeNewswire) -11.90% +33.98%

Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moreadith Randall	Chief Scientific Officer	Feb 02 '26	Option Exercise	0.06	6,500	390	6,500	Feb 03 12:35 PM
Moreadith Randall	Chief Scientific Officer	Feb 02 '26	Sale	3.03	6,500	19,680	0	Feb 03 12:35 PM
Moreadith Randall	Chief Scientific Officer	Jan 28 '26	Option Exercise	0.06	6,500	390	6,500	Jan 29 12:54 PM
Moreadith Randall	Chief Scientific Officer	Jan 28 '26	Sale	3.57	6,500	23,186	0	Jan 29 12:54 PM
Moreadith Randall	Chief Scientific Officer	Jan 22 '26	Option Exercise	0.06	2,500	150	2,500	Jan 23 12:35 PM
Moreadith Randall	Chief Scientific Officer	Jan 22 '26	Sale	2.95	2,500	7,375	0	Jan 23 12:35 PM
Moreadith Randall	Chief Scientific Officer	Jan 20 '26	Option Exercise	0.06	2,000	120	2,000	Jan 21 07:17 PM
Moreadith Randall	Chief Scientific Officer	Jan 21 '26	Option Exercise	0.06	2,000	120	2,000	Jan 21 07:17 PM
Moreadith Randall	Chief Scientific Officer	Jan 20 '26	Sale	3.07	2,000	6,140	0	Jan 21 07:17 PM
Moreadith Randall	Chief Scientific Officer	Jan 21 '26	Sale	3.00	2,000	6,000	0	Jan 21 07:17 PM
Moreadith Randall	Officer	Jan 20 '26	Proposed Sale	3.07	91,000	279,370		Jan 20 04:20 PM
Moreadith Randall	Chief Scientific Officer	Jan 13 '26	Option Exercise	0.06	5,416	325	5,416	Jan 14 12:56 PM
Moreadith Randall	Chief Scientific Officer	Jan 14 '26	Option Exercise	0.06	1,084	65	1,084	Jan 14 12:56 PM
Moreadith Randall	Chief Scientific Officer	Jan 13 '26	Sale	2.50	5,416	13,540	0	Jan 14 12:56 PM
Moreadith Randall	Chief Scientific Officer	Jan 14 '26	Sale	2.50	1,084	2,713	0	Jan 14 12:56 PM
Moreadith Randall	Chief Scientific Officer	Jan 08 '26	Option Exercise	0.06	13,000	780	13,000	Jan 09 12:27 PM
Moreadith Randall	Chief Scientific Officer	Jan 08 '26	Sale	2.69	13,000	34,953	0	Jan 09 12:27 PM
Moreadith Randall	Chief Scientific Officer	Dec 23 '25	Option Exercise	0.06	4,100	246	4,100	Dec 29 11:40 AM
Moreadith Randall	Chief Scientific Officer	Dec 23 '25	Sale	2.60	4,100	10,660	0	Dec 29 11:40 AM
Moreadith Randall	Chief Scientific Officer	Dec 22 '25	Option Exercise	0.06	5,673	340	5,673	Dec 23 02:04 PM
Moreadith Randall	Chief Scientific Officer	Dec 22 '25	Sale	2.67	5,673	15,168	0	Dec 23 02:04 PM
Moreadith Randall	Chief Scientific Officer	Dec 16 '25	Option Exercise	0.06	3,227	194	3,227	Dec 17 07:56 PM
Moreadith Randall	Chief Scientific Officer	Dec 16 '25	Sale	2.96	3,227	9,562	0	Dec 17 07:56 PM
Moreadith Randall	Chief Scientific Officer	Dec 12 '25	Option Exercise	0.06	1,700	102	1,700	Dec 16 06:59 PM
Moreadith Randall	Chief Scientific Officer	Dec 12 '25	Sale	3.26	1,700	5,541	0	Dec 16 06:59 PM
Moreadith Randall	Chief Scientific Officer	Dec 11 '25	Option Exercise	0.06	3,555	213	3,555	Dec 12 12:48 PM
Moreadith Randall	Chief Scientific Officer	Dec 11 '25	Sale	3.24	3,555	11,520	0	Dec 12 12:48 PM
Moreadith Randall	Chief Scientific Officer	Dec 09 '25	Option Exercise	0.06	600	36	600	Dec 11 04:11 PM
Moreadith Randall	Chief Scientific Officer	Dec 10 '25	Sale	3.35	645	2,161	0	Dec 11 04:11 PM
Moreadith Randall	Chief Scientific Officer	Dec 09 '25	Sale	3.31	600	1,988	0	Dec 11 04:11 PM
Moreadith Randall	Chief Scientific Officer	Dec 03 '25	Option Exercise	0.06	5,000	300	5,000	Dec 04 07:56 PM
Moreadith Randall	Chief Scientific Officer	Dec 02 '25	Option Exercise	0.06	1,500	90	1,500	Dec 04 07:56 PM
Moreadith Randall	Chief Scientific Officer	Dec 03 '25	Sale	3.52	5,000	17,623	0	Dec 04 07:56 PM
Moreadith Randall	Chief Scientific Officer	Dec 02 '25	Sale	3.91	1,500	5,858	0	Dec 04 07:56 PM
Moreadith Randall	Chief Scientific Officer	Nov 25 '25	Option Exercise	0.06	5,965	358	11,930	Nov 26 05:21 PM
Moreadith Randall	Chief Scientific Officer	Nov 25 '25	Sale	3.90	5,965	23,264	5,965	Nov 26 05:21 PM
Moreadith Randall	Chief Scientific Officer	Nov 24 '25	Option Exercise	0.06	535	32	535	Nov 25 09:20 PM
Moreadith Randall	Chief Scientific Officer	Nov 24 '25	Sale	3.94	535	2,105	0	Nov 25 09:20 PM
Moreadith Randall	Chief Scientific Officer	Nov 18 '25	Option Exercise	0.06	6,500	390	6,500	Nov 19 01:47 PM
Moreadith Randall	Chief Scientific Officer	Nov 18 '25	Sale	3.75	6,500	24,402	0	Nov 19 01:47 PM
Moreadith Randall	Chief Scientific Officer	Nov 10 '25	Option Exercise	0.06	6,500	390	6,500	Nov 12 12:38 PM
Moreadith Randall	Chief Scientific Officer	Nov 10 '25	Sale	4.10	6,500	26,650	0	Nov 12 12:38 PM
Moreadith Randall	Chief Scientific Officer	Nov 05 '25	Option Exercise	0.06	3,398	204	3,398	Nov 06 04:40 PM
Moreadith Randall	Chief Scientific Officer	Nov 05 '25	Sale	4.24	3,398	14,408	0	Nov 06 04:40 PM
Moreadith Randall	Chief Scientific Officer	Nov 04 '25	Option Exercise	0.06	3,102	186	3,102	Nov 05 03:29 PM
Moreadith Randall	Chief Scientific Officer	Nov 04 '25	Sale	4.40	3,102	13,634	0	Nov 05 03:29 PM
Moreadith Randall	Chief Scientific Officer	Oct 28 '25	Option Exercise	0.06	5,551	333	5,551	Oct 29 05:04 PM
Moreadith Randall	Chief Scientific Officer	Oct 28 '25	Sale	4.96	5,551	27,541	0	Oct 29 05:04 PM
Moreadith Randall	Chief Scientific Officer	Oct 27 '25	Option Exercise	0.06	949	57	949	Oct 28 01:22 PM
Moreadith Randall	Chief Scientific Officer	Oct 27 '25	Sale	5.19	949	4,921	0	Oct 28 01:22 PM
Moreadith Randall	Chief Scientific Officer	Oct 20 '25	Option Exercise	0.06	6,500	390	6,500	Oct 21 12:24 PM
Moreadith Randall	Chief Scientific Officer	Oct 20 '25	Sale	4.97	6,500	32,287	0	Oct 21 12:24 PM
Moreadith Randall	Officer	Oct 13 '25	Proposed Sale	5.97	88,826	530,158		Oct 14 04:48 PM
Moreadith Randall	Chief Scientific Officer	Oct 13 '25	Option Exercise	0.06	4,326	260	4,326	Oct 14 01:16 PM
Moreadith Randall	Chief Scientific Officer	Oct 13 '25	Sale	5.20	4,326	22,495	0	Oct 14 01:16 PM
Moreadith Randall	Chief Scientific Officer	Aug 26 '25	Option Exercise	0.06	45,632	2,738	45,632	Aug 27 05:16 PM
Moreadith Randall	Chief Scientific Officer	Aug 25 '25	Option Exercise	0.06	2,042	123	2,042	Aug 27 05:16 PM
Moreadith Randall	Chief Scientific Officer	Aug 26 '25	Sale	7.01	45,632	319,880	0	Aug 27 05:16 PM
Moreadith Randall	Chief Scientific Officer	Aug 25 '25	Sale	5.65	2,042	11,537	0	Aug 27 05:16 PM
Moreadith Randall	Chief Scientific Officer	Aug 18 '25	Option Exercise	0.06	2,227	134	2,227	Aug 20 05:13 PM
Moreadith Randall	Chief Scientific Officer	Aug 20 '25	Option Exercise	0.06	2,077	125	2,077	Aug 20 05:13 PM
Moreadith Randall	Chief Scientific Officer	Aug 18 '25	Sale	5.25	2,227	11,692	0	Aug 20 05:13 PM
Moreadith Randall	Chief Scientific Officer	Aug 20 '25	Sale	5.10	2,077	10,593	0	Aug 20 05:13 PM
Moreadith Randall	Chief Scientific Officer	Aug 12 '25	Option Exercise	0.06	5,500	330	5,500	Aug 14 04:27 PM
Moreadith Randall	Chief Scientific Officer	Aug 12 '25	Sale	5.25	5,500	28,875	0	Aug 14 04:27 PM
Moreadith Randall	Chief Scientific Officer	Aug 04 '25	Option Exercise	0.06	5,500	330	5,500	Aug 06 05:22 PM
Moreadith Randall	Chief Scientific Officer	Aug 04 '25	Sale	5.17	5,500	28,435	0	Aug 06 05:22 PM
Moreadith Randall	Chief Scientific Officer	Jul 29 '25	Option Exercise	0.06	4,196	252	4,196	Jul 30 01:47 PM
Moreadith Randall	Chief Scientific Officer	Jul 29 '25	Sale	6.50	4,196	27,274	0	Jul 30 01:47 PM
Moreadith Randall	Chief Scientific Officer	Jul 28 '25	Option Exercise	0.06	6,500	390	6,500	Jul 29 06:10 AM
Moreadith Randall	Chief Scientific Officer	Jul 28 '25	Sale	5.89	6,500	38,285	0	Jul 29 06:10 AM
Moreadith Randall	Chief Scientific Officer	Jul 21 '25	Option Exercise	0.06	6,500	390	6,500	Jul 22 10:25 AM
Moreadith Randall	Chief Scientific Officer	Jul 21 '25	Sale	5.34	6,500	34,710	0	Jul 22 10:25 AM
Moreadith Randall	Chief Scientific Officer	Jul 14 '25	Option Exercise	0.06	6,500	390	6,500	Jul 17 10:40 AM
Moreadith Randall	Chief Scientific Officer	Jul 14 '25	Sale	5.01	6,500	32,565	0	Jul 17 10:40 AM
Moreadith Randall	Chief Scientific Officer	Jul 07 '25	Option Exercise	0.06	6,500	390	6,500	Jul 09 10:47 AM
Moreadith Randall	Chief Scientific Officer	Jul 07 '25	Sale	5.67	6,500	36,855	0	Jul 09 10:47 AM
Moreadith Randall	Chief Scientific Officer	Jun 30 '25	Option Exercise	0.06	6,500	390	6,500	Jul 02 11:00 AM
Moreadith Randall	Chief Scientific Officer	Jun 30 '25	Sale	5.78	6,500	37,570	0	Jul 02 11:00 AM
Moreadith Randall	Officer	Jun 30 '25	Proposed Sale	5.78	99,674	576,056		Jun 30 04:28 PM

BHVN

Biohaven Ltd

SER

Serina Therapeutics Inc

Upgrade your FINVIZ experience